These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16389172)

  • 41. Value-based insurance design in oncology.
    de Souza JA; Polite BN; Manning WG; Fendrick AM; Ratain MJ
    Lancet Oncol; 2011 Apr; 12(4):321-3. PubMed ID: 21463832
    [No Abstract]   [Full Text] [Related]  

  • 42. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.
    Nerich V; Borg C; Villanueva C; Thiery-Vuillemin A; Helias P; Rohrlich PS; Demarchi M; Pivot X; Limat S
    J Oncol Pharm Pract; 2013 Mar; 19(1):8-17. PubMed ID: 22623276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-minimisation analysis of pegylated liposomal doxorubicin hydrochloride versus topotecan in the treatment of patients with recurrent epithelial ovarian cancer in Spain.
    Ojeda B; de Sande LM; Casado A; Merino P; Casado MA
    Br J Cancer; 2003 Sep; 89(6):1002-7. PubMed ID: 12966416
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
    Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
    Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Keynote comment: Cancer drug pricing in the USA.
    Johnson DH
    Lancet Oncol; 2006 Jun; 7(6):444-5. PubMed ID: 16750490
    [No Abstract]   [Full Text] [Related]  

  • 46. Innovative New Drugs for Serious Nonlethal Diseases: The Cost to Develop and the Cost to Buy.
    Eaglstein WH
    JAMA Dermatol; 2016 Feb; 152(2):139-40. PubMed ID: 26606648
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug Pricing Trends for Orally Administered Anticancer Medications Reimbursed by Commercial Health Plans, 2000-2014.
    Dusetzina SB
    JAMA Oncol; 2016 Jul; 2(7):960-1. PubMed ID: 27123993
    [No Abstract]   [Full Text] [Related]  

  • 48. [The cost of chemotherapy].
    Lévy C; Bonastre J
    Bull Cancer; 2003 Nov; 90(11):976-82. PubMed ID: 14706901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Economic aspects of the new Spanish laws on pharmaceutical preparations.
    Antoñanzas F; Oliva J; Pinillos M; Juàrez C
    Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
    Drummond M; Evans B; LeLorier J; Karakiewicz P; Martin D; Tugwell P; MacLeod S
    Can J Clin Pharmacol; 2009; 16(2):e273-81; discussion e282-4. PubMed ID: 19439771
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Biosimilar products--cheaper version of biological drugs. New possibilities within several therapeutic fields].
    Mellstedt H
    Lakartidningen; 2009 Jun 3-9; 106(23):1563-6. PubMed ID: 19583014
    [No Abstract]   [Full Text] [Related]  

  • 52. The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?
    Alifrangis C; Krell J; Stebbing J
    Eur J Cancer; 2011 Jun; 47(9):1285-6. PubMed ID: 21550231
    [No Abstract]   [Full Text] [Related]  

  • 53. An economic model to reduce the cost of chemotherapy for gynecologic cancer.
    Jacobs VR; Thoedtmann J; Brunner B; Kiechle M
    Int J Fertil Womens Med; 2004; 49(6):274-7. PubMed ID: 15751266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Focusing pharmacoeconomic activities: reimbursement or the drug life cycle?
    Langley PC
    Curr Med Res Opin; 2004; 20(2):181-8. PubMed ID: 15006012
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Methodology of pharmacoeconomic studies in oncology].
    Ballatori E
    Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of health economic information by reimbursement authorities.
    Drummond MF
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii60-3. PubMed ID: 14585919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bad month for cancer care in the UK.
    Lancet Oncol; 2010 Aug; 11(8):701. PubMed ID: 20688267
    [No Abstract]   [Full Text] [Related]  

  • 58. Targeted Cancer Therapies World Congress 2010--part 1. 21-23 September 2010, Zurich, Switzerland.
    Youssoufian H
    IDrugs; 2010 Dec; 13(12):830-2. PubMed ID: 21154136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimum cancer care--an unaffordable goal?
    Ludwig H
    Lancet Oncol; 2004 Sep; 5(9):529-30. PubMed ID: 15337480
    [No Abstract]   [Full Text] [Related]  

  • 60. Pricing and reimbursement of pharmaceuticals: an evaluation of cost-containment strategies. Proceedings of a symposium. Talloires, France, July 21-22, 1993.
    Pharmacoeconomics; 1994; 6 Suppl 1():1-87. PubMed ID: 10184441
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.